Chai Discovery announces $400M Series C funding
The round will advance AI-driven molecular design for drug discovery.
See the latest news and media coverage for Chai Discovery. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI company predicting and reprogramming biochemical interactions
chaidiscovery.comLast updated
In short: Chai Discovery secured $400 million in Series C funding, reaching a $3.8 billion valuation to advance its AI-driven molecular design.
The round will advance AI-driven molecular design for drug discovery.
Novartis will use Chai's AI models to discover antibodies across multiple targets, building on prior technical engagement.
Led by General Catalyst and Oak HC/FT, with Thrive Capital, OpenAI, and others participating. Annie Lamont and Hemant Taneja join the board. Funds support research and team growth.
Chai-2 designs full-length mAbs with high developability, atomic precision via Cryo-EM, and success against hard targets like GPCRs and peptide-MHC.
The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to ...
Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with ...
Chai Discovery, the AI company engineering models to discover new molecules, today announced that certain Chai Discovery frontier AI model capabilities will be made available...
Pfizer (NYSE:PFE) has entered a new licensing agreement with Chai Discovery to use artificial...
Track Chai Discovery and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Chai Discovery and other trending companies.